Key facts
- It has raised $13.8M; the latest was Later Stage VC ($13.8M) in May 2025.
- Notable investors include Li Ning (China) Sports Goods.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Feilikang Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Feilikang Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Feilikang Pharmaceutical
Manufacturer of innovative pharmaceuticals and provider of drug R&D technology services aims to advance high-value, novel, and specialized therapeutic solutions. The company's offerings feature the development of new chemical entities, innovative dosage forms, proprietary process technologies, and integrated R&D-to-manufacturing transfer capabilities, enabling customers to overcome technical barriers, enhance drug efficacy and quality, and accelerate the commercialization of advanced pharmaceutical products.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2014
- Ownership
- Privately Held (backing)
Feilikang Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Feilikang Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Feilikang Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.